Please use this identifier to cite or link to this item:
Title: The present and future of prostate cancer urine biomarkers
Author: Rigau, Marina
Olivan Riera, Mireia
Garcia, Marta
Sequeiros, Tamara
Montes, Melania
Colás, Eva
Llauradó, Marta
Planas, Jacques
Torres, Inés de
Morote, Juan
Cooper, Colin
Reventós Puigjaner, Jaume
Clark, Jeremy
Doll, Andreas
Keywords: Càncer de pròstata
Indicadors biològics
Prostate cancer
Indicators (Biology)
Issue Date: 17-Jun-2013
Publisher: MDPI
Abstract: In order to successfully cure patients with prostate cancer (PCa), it is important to detect the disease at an early stage. The existing clinical biomarkers for PCa are not ideal, since they cannot specifically differentiate between those patients who should be treated immediately and those who should avoid over-treatment. Current screening techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. In recent years, the utilization of urine has emerged as an attractive option for the non-invasive detection of PCa. Moreover, a great improvement in high-throughput 'omic' techniques has presented considerable opportunities for the identification of new biomarkers. Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field.
Note: Reproducció del document publicat a:
It is part of: International Journal of Molecular Sciences, 2013, vol. 14, num. 6, p. 12620-12649
Related resource:
ISSN: 1661-6596
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
700443.pdf2.11 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons